LOS ANGELES, CA--(Marketwire -03/28/12)- Mark A. Sirgo is the President and CEO of BioDelivery Sciences International, Inc. (NASDAQ: BDSI - News). After spending more than 20 years in the pharmaceutical industry with companies like GlaxoSmithKline and others, Sirgo joined the company in August 2004 as Senior Vice President of Commercialization and Corporate Development upon the acquisition of Arius Pharmaceuticals, which he co-founded.
Today, in an exclusive video interview with BioMedReports, Sirgo answers questions about BioDelivery's platform, partners and unique pipeline products. In addition, he tells investors about some of the key characteristics which set BDSI apart in the market.
"The two products in our pipeline have much greater value than our first product," explains Dr. Sirgo. "We've demonstrated the ability to move products through the regulatory hurdles. Investors need to take a closer look at our pipeline and the value that we plan to create there.
"We have one marketed product that uses the same technology that products in our pipeline are using. It's approved. It's been through the FDA and it serves as a great proof-of-concept for our ability to not only take our product through the regulatory pathway, but also partner and get through commercialization."
The full video interview with Mark A. Sirgo, CEO of BioDelivery Sciences International, is now available at:
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:
News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports
BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com